Download presentation
Presentation is loading. Please wait.
Published byΘεοδοσία Τομαραίοι Modified over 5 years ago
1
Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD, Daniel B. Costa, MD, PhD, Deepa Rangachari, MD Journal of Thoracic Oncology Volume 12, Issue 4, Pages e35-e36 (April 2017) DOI: /j.jtho Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions
2
Figure 1 Radiographic response and progression of disease over time: baseline disease at diagnosis of metastasis (A), response to first-line erlotinib (B), disease progression during erlotinib therapy (C), and response to second-line osimertinib (D). Journal of Thoracic Oncology , e35-e36DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.